Get In Touch

Interstitial cystitis (IC), also known as painful bladder syndrome, is a chronic bladder issue often associated with bladder pressure and pain, with occasional pain in either the lower abdomen, pelvic, or lower back. The patient could experience pain raging from mild to severe. The pelvic nerve signal to the brain gets mixed up in an individual suffering from interstitial cystitis. Consequently, an urgency to urinate, often in a small volume, is observed. On an average, a person urinates seven times a day; however, in severe cases of IC, urination may occur around 40-60 times a day. IC is not an infection, but is often mistaken to be a bladder infection. Factors contributing to interstitial cystitis are: a defect of the epithelium layer of the bladder, leaking epithelium allows toxic agents in urine to irritate the bladder wall. Other anticipated, but not clear, contributing factors include heredity, an autoimmune reaction, infection or allergy. Various therapies and medication may provide relief from the symptoms for IC; however, there is still no cure for this disease.

Studies conducted on interstitial cystitis and associated data have shown that it is thrice more prevalent in women than in men, and the risk increases with age. The female-to-male ratio is estimated to be 10:1. It is estimated that around 1 to4 million men and 3 to8 million women suffer from IC. Rise in prevalence of IC stimulates the research and development on the drug, as it is likely to provide an appropriate environment for newer products to be profitable. The prevalence of IC is estimated to be between 2.7% to 6.53% among older women in the United States. Patients suffering from other conditions such as fibromyalgia, irritable bowel syndrome, or allergies often experience IC. According to a publication by National Institutes of Health (NIH), in 2012, the annual expenditure for medication for the geriatric population aged ≥65 years who are Medicare beneficiaries was US$ 249,160,233 (nonspecific and specific IC combined).

IC is mainly diagnosed by urine analysis, bladder ultrasound, cystoscopy, biopsy of bladder and urethra, bladder stretching, and prostrate fluid culture. The main goal is to relieve the symptoms of IC, and thus treatment is segmented into five phases: First phase by Physical therapy, second phase treatment by oral medication such as Amitriptyline – to regulate the bladder spasms, Pentosan (Elmiron) – helps rebuild the tissue lining the bladder, hydroxyzine, use of steroids, and dimethyl sulfoxide to treat severe IC conditions by blocking the pain and reducing the inflammation is also recommended. The third phase is neurostimulation - transcutaneous electrical nerve stimulation or sacral nerve stimulation. The fourth phase includes administering cyclosporine to alter the immune response on the bladder, and the fifth phase involves bladder detention or surgery. The market currently has only two approved treatment options for IC: Elmiron (pentosan polysulfate sodium) and Rimso-50 (dimethyl sulfoxide). Elmiron was approved on September 26, 1996, and its patent expired on January 19, 2010. Similarly, Rimso-50 was approved prior to January 1, 1982, and its patent expired before 2002. The current line of treatment is dominated by off-label drug options such as antidepressants (amitriptyline), antihistamines (hydroxyzine), and analgesics (opioid and non-steroidal) due to the limited availability of approved therapies.

The IC therapeutics market is currently weak due to limitations regarding the efficacy and compliance of available products. Other factors contributing to the significant unmet needs include limited approved treatment options, lack of awareness, and need for disease modifying therapies. Current pipeline for the IC therapeutics market is very weak with a majority of the molecules in the early stage of development. These significant unmet needs and weak pipeline with a majority of the molecules in early stage pose new opportunities for new entrants.

In terms of geography, the interstitial cystitis market can be segmented into North America, Europe, Asia Pacific, and Rest of the World (RoW). The interstitial cystitis market is estimated to expand at a sluggish rate primarily due to the limited availability of approved products, low diagnosis rate, and lack of new product approvals.

Key players operating in the interstitial cystitis market are Aquinox Pharmaceuticals Inc., Astellas Pharma Inc, Merck & Co Inc, Allergan Plc., Kytogenics Pharmaceuticals Inc., BELLUS Health Inc, UCB SA, Lipella Pharmaceuticals Inc, Urigen Pharmaceuticals Inc, and Xigen SA.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Interstitial Cystitis Market